Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
First-in-human phase 1 study of TAK-931 for solid tumours

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 805

Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan

Dr Shimizu speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about phase I trials for CDC7 inhibitor TAK-931.

He outlines the scheduling of this first-in-human trial, including dosage escalation and de-escalation upon reaching a maximum tolerated dose, and management of adverse events.

Dr Shimizu summarises the pharmacokinetic profile and response rates, and next steps for further trials.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation